Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 82.6%

Neg 0% Neu 0% Pos 82.6%

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price target from $27 to $29.